Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis...
1 insider purchase on record · latest filing 2007-11-13.
Insiders have also filed 71 sale transactions at EQ.